Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy

Annals of Pharmacotherapy

Volumn 34, Issue 6, 2000, Pages 737-739

  English, Kerri E ^a   Brien, William F ^b   Howson Jan, Kang ^a   Kovacs, Michael J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic myelogenous leukemia; Factor VIII; Interferon alfa

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING INHIBITOR; HYDROXYUREA; PREDNISONE; RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; BLEEDING; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HEMOPHILIA; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FACTOR VIII; HEMORRHAGE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID; MALE; MIDDLE AGED;

EID: 0034042096     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19330     Document Type: Article

References (25)

1. Hoffman MA, Wadler S. Mechanisms by which interferon potentiates chemotherapy. Cancer Invest 1993;11:310-3.
2. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-92.
3. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-9.
4. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-α therapy. J Rheumatol 1994;21:350-2.
5. Urabe A. Interferons for the treatment of hematological malignancies. Oncology 1994;51:137-41.
6. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α. Semin Oncol 1998;25:3-8.
7. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A. Br J Haematol 1994;87:434-6.
8. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytarabine. J Clin Oncol 1999;17:284-92.
9. Weiss K. Safety profile of interferon-α therapy. Semin Oncol 1998;25:9-13.
10. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease patients receiving alpha-interferon therapy. Cancer 1990;65:2237-42.
11. Sallah S. Inhibitors to clotting factors. Ann Hematol 1997;75:1-8.
12. Komminoth A, Dufour P, Bergerat JP, Wiesel ML, Falkenrodt A, Oberling F. Hairy cell leukemia and factor VIII inhibitor: a case report. Nouv Rev Fr Hematol 1992;34:269-71.
13. Hultin MB. Acquired inhibitors in malignant and nonmalignant disease states. Am J Med 1991;9(suppl):5A-9S-5A-13S.
14. Harada Y, Iwai M, Miyoshi M, Ueda Y, Mitsufuji S, Seiki K, et al. Life-threatening hemorrhage in a patient with gastric cancer and acquired hemophilia. Am J Gastroenterol 1998;93:1372-3.
15. Longo G, Luppi M, Ferrara L, Torelli U, Barbieri U, Torelli G. Acquired factor VIII inhibitor at the onset of prolymphocytic leukemia. Leukemia 1996;10:1557-8.
16. Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998;105:400-8.
17. Kelsey PR, Leyland MJ. Acquired inhibitor to human factor VIII associated with paraproteinaemia and subsequent development of chronic lymphatic leukemia. Br Med J 1982;285:174-5.
18. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemostas 1981;45:200-3.
19. Meek JCE, Haak HL. Acute myelomonocytic leukaemia and acquired haemophilia A with severe cutaneous haemorrhage. Scand J Haematol 1986;37:168-73.
20. López R, Mateo J, Cruz, J, LópeZ A, Urrutia T, Fontcuberta J. Presentation of an acquired factor VIII inhibitor with a muscular haematoma mimicking a deep venous thrombosis in a patient with breast cancer. Blood Coagulation and Fibrinolysis 1995;6:680-2.
21. Lionnet F, Pulik M, Genet P, Lucas G, Sollet JP. Acquired factor VIII inhibitor associated with a prostatic cancer: simultaneous occurrence and healing. Thromb Haemostas 1995;73:324-9.
22. Shastri KA, Logue GL, Zeid MY, Behrens AN, Lenahan EJ, Haar JG. Acquired factor VIII inhibitor with squamous cell cancer of the epiglottis. Arch Otolaryngol Head Neck Surg 1990;116:350-3.
23. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology 1999;13:169-84.
24. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gurterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991;114:532-8.
25. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.